Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Sintilimab in ICI-pretreated advanced liver cancer
NCT05010681Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and lenvatinib in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Primary endpoint: Objective Response Rate up to 24 months. Started Aug 2021; status: recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05010681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010681.